AbbVie announced positive topline results from its Phase 3b/4 SELECT-SWITCH study, a head-to-head trial comparing Rinvoq (upadacitinib) to Humira (adalimumab) in adults with moderate to severe rheumatoid arthritis who had an inadequate response to another TNF inhibitor. The study met its primary endpoint, with a significantly higher proportion of patients treated with Rinvoq achieving low disease activity and remission at week 12 compared to those on Humira. These results are significant as they provide direct evidence of Rinvoq's superiority in a specific patient population, potentially strengthening its position in the competitive immunology market. The safety profile for Rinvoq was consistent with previous studies, and no new safety risks were identified during the trial. Following the news, AbbVie's stock saw a modest increase, trading up by 0.54% at $230.82.